Ultimovacs Overview

  • Founded
  • 2011

Founded
  • Status
  • Public

  • Employees
  • 21

Employees
  • Stock Symbol
  • ULTI

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $11.99

  • (As of Wednesday Closing)

Ultimovacs General Information

Description

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
OSL
Primary Office
  • Ullernchausséen 64
  • 0379 Oslo
  • Norway
+47 413 00 000

Ultimovacs Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ultimovacs Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.99 $11.74 $5.44 - $13.27 $413M 34.4M 47.9K -$0.47

Ultimovacs Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 142,834 398,244 251,846 78,800
Revenue 0 0 0 0
EBITDA (17,578) (19,103) (12,911) (7,313)
Net Income (15,973) (19,100) (12,740) (6,948)
Total Assets 51,456 74,314 62,051 54,203
Total Debt 168 236 443 411
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ultimovacs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ultimovacs‘s full profile, request access.

Request a free trial

Ultimovacs Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product cand
Drug Discovery
Oslo, Norway
21 As of 2022
00000
000000000 00000

000000

s nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000 000000000
Oslo, Norway
00 As of 0000
0000000000 0

000000

niam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo co
0000 000000000
Vienna, Austria
00 As of 0000
000.00
0000000000 0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ultimovacs Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zelluna Immunotherapy Venture Capital-Backed Oslo, Norway 00 0000000000 0
0000000 000000000 Venture Capital-Backed Vienna, Austria 00 000.00 0000000000 0
00000000 Formerly VC-backed Mainz, Germany 0000 00.000 00000000 00.000
00000000 Formerly VC-backed Tubingen, Germany 000 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed Bedford, MA 00 000.00 0000000000 0 000.00
You’re viewing 5 of 10 competitors. Get the full list »

Ultimovacs Patents

Ultimovacs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017275782-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Pending 02-Jun-2016 00000000000
CA-3026172-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Pending 02-Jun-2016 00000000000
EP-3463436-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Pending 02-Jun-2016 0000000000000
US-20190247482-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Active 02-Jun-2016 0000000000000
US-11419927-B2 Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Active 02-Jun-2016 A61K39/0011 00
To view Ultimovacs’s complete patent history, request access »

Ultimovacs Executive Team (10)

Name Title Board Seat Contact Info
Carlos de Sousa MD Chief Executive Officer
Hans Eid Chief Financial Officer, Finance
Audun Tornes Chief Technology Officer
Sara Mangsbo Ph.D Chief Development Officer & Chief Innovation Officer
Gustav Gaudernack Chief Scientific Officer
You’re viewing 5 of 10 executive team members. Get the full list »

Ultimovacs Board Members (12)

Name Representing Role Since
000000 00000 00.0 Self Board Member 000 0000
00000 00000000 000 Self Board Member 000 0000
00ø00 00000000 Gjelsten Holding Board Member 000 0000
000 0000000 Ultimovacs Board Member 000 0000
000000 0000000 Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Ultimovacs Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ultimovacs Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ultimovacs‘s full profile, request access.

Request a free trial

Ultimovacs Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 30-Jan-2022 00000 0000 0000 Entertainment Software
Immuneed 11-Jul-2018 Buyout/LBO 00.000 Drug Discovery 0000 0000
To view Ultimovacs’s complete investments history, request access »

Ultimovacs Subsidiaries (1)

Company Name Industry Location Founded
00000000 Drug Discovery Uppsala, Sweden 0000
To view Ultimovacs’s complete subsidiaries history, request access »

Ultimovacs ESG

Risk Overview

Risk Rating

Updated July, 19, 2022

19.54 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

0.0

Percentile

Biotechnology

Subindustry

00 of 465

Rank

0.00

Percentile

To view Ultimovacs’s complete esg history, request access »